Atenolol Tablets 25mg (Atenolol Tablets Sawai® / アテノロール錠25mg「サワイ」)

JPY ¥1,200

Japanese Cardioselective Beta-Blocker (Atenolol 25mg). Oral tablet for hypertension, angina pectoris, and tachyarrhythmias. 100 tablets (10 tablets x 10). Mfd. by Sawai Pharmaceutical Co., Ltd., Japan.

Bulk deal
Quantity Discount Discounted price
5 - 9 8% JPY ¥1,104
10 - 19 12% JPY ¥1,056
20 + 18% JPY ¥984
SKU: ATE-25-TAB Category:

Description

Product Overview / 商品概要

Atenolol Tablets 25mg “Sawai” (アテノロール錠25mg「サワイ」)
Generic: Atenolol / アテノロール
Therapeutic Category: Cardioselective Beta-Blocker / 心臓選択性β遮断剤
Manufactured by: Sawai Pharmaceutical Co., Ltd. / 沢井製薬株式会社

Composition & Specification / 組成・規格

Active Ingredient: Atenolol (JP) 25mg per tablet / 1錠中 日局アテノロール 25mg
Additives: Glycerin, Titanium oxide, Magnesium stearate, Gelatin, Magnesium carbonate, Corn starch, Hypromellose, Macrogol 6000, Sodium lauryl sulfate / グリセリン、酸化チタン、ステアリン酸Mg、ゼラチン、炭酸Mg、トウモロコシデンプン、ヒプロメロース、マクロゴール6000、ラウリル硫酸Na
Appearance: White film-coated tablet, diameter 6.6mm, thickness 3.2mm, weight approx. 108mg, identification code: SW 521
外観: 白色、フィルムコーティング錠、直径6.6mm、厚さ3.2mm、重量約108mg、識別コード SW 521

Indications / 効能効果

EN: Essential hypertension (mild to moderate); Angina pectoris; Tachyarrhythmias (sinus tachycardia, extrasystoles)
JA: ○本態性高血圧症(軽症~中等症)
○狭心症
○頻脈性不整脈(洞性頻脈、期外収縮)

Dosage and Administration / 用法用量

EN: The usual adult dose is 2 tablets (50mg as atenolol) once daily orally. The dose may be adjusted according to age and symptoms, but the maximum dose is 4 tablets (100mg) once daily.
JA: 通常成人には2錠(アテノロールとして50mg)を1日1回経口投与する。なお、年齢、症状により適宜増減できるが、最高量は1日1回4錠(100mg)までとする。

Contraindications / 禁忌

EN: Patients with a history of hypersensitivity to any component of this product; diabetic ketoacidosis or metabolic acidosis; severe or symptomatic bradycardia, AV block (grade II or III), sinoatrial block, or sick sinus syndrome; cardiogenic shock; right heart failure due to pulmonary hypertension; congestive heart failure; hypotension; severe peripheral circulatory disorders (e.g., gangrene); untreated pheochromocytoma or paraganglioma
JA: 本剤の成分に対し過敏症の既往歴のある患者、糖尿病性ケトアシドーシス・代謝性アシドーシスのある患者、高度又は症状を呈する徐脈・房室ブロック(Ⅱ、Ⅲ度)・洞房ブロック・洞不全症候群のある患者、心原性ショックのある患者、肺高血圧による右心不全のある患者、うっ血性心不全のある患者、低血圧症の患者、重度の末梢循環障害のある患者(壊疽等)、未治療の褐色細胞腫又はパラガングリオーマの患者

Regulatory Information / 規制情報

Approval No.: 22400AMX00942000
Sales Started: June 2009 / 2009年6月
Classification Code: 872123
Storage: Store at room temperature / 室温保存
Shelf Life: 3 years / 3年

Packaging / 包装

Main Package (for sale): 100 tablets (10 tablets x 10) / 100錠(10錠×10)
Other Available Packages (by special order): PTP: 100 tablets (10 tablets x 10), 500 tablets (10 tablets x 50)

Full product insert (添付文書) is attached as a downloadable PDF. For detailed precautions, drug interactions, and safety information, please refer to the official package insert.

Additional information

重さ 0.15 kg

Reviews

There are no reviews yet.

Be the first to review “Atenolol Tablets 25mg (Atenolol Tablets Sawai® / アテノロール錠25mg「サワイ」)”

メールアドレスが公開されることはありません。 ※ が付いている欄は必須項目です

Export from Japan — Atenolol Tablets 25mg (Atenolol Tablets Sawai®

🏭 Supply & Origin

  • Country of Origin: Japan
  • Regulatory Standard: PMDA (Japan) / GMP Compliant
  • Pharmacopoeia: Japanese Pharmacopoeia (JP)
  • Supplier: Mate Co., Ltd. — Licensed Pharmaceutical Wholesaler (License No. B14309, Osaka)
  • Supply Capacity: Full-line sourcing through Japan's regulated distribution channels

🚚 Shipping & Trade Terms

  • Incoterms: FOB Kansai International Airport (KIX)
  • Shipping: Air freight via B/L or AWB
  • Payment: 100% T/T in advance
  • Lead Time: 2-4 weeks after payment confirmation
  • Available Regions: EU, LATAM, APAC, Middle East, Africa

Request a Quotation

For pricing, MOQ, and regulatory documentation, contact our export team:

Email: kurimoto@mate-osaka.co.jp
Tel: +81-72-665-5736

All exports are conducted through proper regulatory procedures including customs clearance, B/L or AWB documentation, and T/T advance payment. We do not engage in hand-carry, cash transactions, or sales to unlicensed parties.